Controlling neuroinflammation in Alzheimer's disease by targeting specific protein interactions
Targeting p38/MK2 protein-protein interaction to control neuroinflammation in Alzheimer's Disease
This study is exploring a new way to treat Alzheimer's disease by looking at how two proteins work together in the brain, with the hope of creating a treatment that could help patients feel better with fewer side effects.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10889827 on NIH RePORTER |
What this research studies
This research investigates a new approach to treat Alzheimer's disease by focusing on the interaction between two proteins, p38 and MK2, which are involved in neuroinflammation. The study aims to develop small molecules that can disrupt this protein-protein interaction, potentially leading to a more effective treatment for Alzheimer's. By targeting the interaction rather than inhibiting the proteins individually, the research seeks to minimize side effects and improve therapeutic outcomes. Patients may benefit from this innovative strategy if successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing symptoms of dementia related to Alzheimer's.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce neuroinflammation in Alzheimer's disease, potentially slowing disease progression.
How similar studies have performed: While targeting protein-protein interactions is a novel approach in Alzheimer's research, similar strategies have shown promise in other areas of drug development.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Ivanov, Andrey — Emory University
- Study coordinator: Ivanov, Andrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.